Piper Sandler Downgrades Mirati Therapeutics to Neutral, Announces $58 Price Target
Portfolio Pulse from Benzinga Newsdesk
Piper Sandler analyst Joseph Catanzaro has downgraded Mirati Therapeutics (NASDAQ:MRTX) from Overweight to Neutral and set a price target of $58.
October 10, 2023 | 8:57 am
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Mirati Therapeutics has been downgraded from Overweight to Neutral by Piper Sandler, with a new price target of $58.
The downgrade from Overweight to Neutral by Piper Sandler indicates a less optimistic outlook for the company's stock. This could potentially lead to a decrease in the stock's price in the short term. The new price target of $58 also provides a benchmark for investors, which could influence trading decisions.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100